The c-Met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models

Cancers

Volumn 6, Issue 3, 2014, Pages 1736-1752

  Bladt, Friedhelm ^a   Friese Hamim, Manja ^a   Ihling, Christian ^a   Wilm, Claudia ^a   Blaukat, Andree ^a  

^a Merck Serono GmbH   (Germany)

Author keywords

C Met; Hepatocellular carcinoma; Hepatocyte growth factor; MSC2156119J; Receptor tyrosine kinase; Sorafenib; Xenograft models

Indexed keywords

ALPHA FETOPROTEIN; EMD 1214063; RAPAMYCIN; SORAFENIB; TEPOTINIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84925543792     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6031736     Document Type: Article

References (36)

1. Borowiak, M.; Garratt, A.N.; Wüstefeld, T.; Strehle, M.; Trautwein, C.; Birchmeier, C. Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. USA 2004, 101, 10608-10613.
2. Sakata, H.; Takayama, H.; Sharp, R.; Rubin, J.S.; Merlino, G.; LaRochelle, W.J. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 1996, 7, 1513-1523.
3. Jung, K.H.; Park, B.H.; Hong, S.S. Progress in cancer therapy targeting c-Met signaling pathway. Arch. Pharm. Res. 2012, 35, 595-604.
4. You, H.; Ding, W.; Dang, H.; Jiang, Y.; Rountree, C.B. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011, 54, 879-889.
5. Eder, J.P.; vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin. Cancer Res. 2009, 15, 2207-2214.
6. Wang, R.; Ferrell, L.D.; Faouzi, S.; Maher, J.J.; Bishop, J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 2001, 153, 1023-1034.
7. Tward, A.D.; Jones, K.D.; Yant, S.; Cheung, S.T.; Fan, S.T.; Chen, X.; Kay, M.A.; Wang, R.; Bishop, J.M. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc. Natl. Acad. Sci. USA 2007, 104, 14771-14776.
8. Chu, J.S.; Ge, F.J.; Zhang, B.; Wang, Y.; Silvestris, N.; Liu, L.J.; Zhao, C.H.; Lin, L.; Brunetti, A.E.; Fu, Y.L.; et al. Expression and prognostic value of VEGFR-2, PDGFR-ß, and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2013, 32, 16.
9. Goyal, L.; Muzumdar, M.D.; Zhu, A.X. Targeting the HGF/c-Met pathway in hepatocellular carcinoma. Clin. Cancer Res. 2013, 19, 2310-2318.
10. Inagaki, Y.; Qi, F.; Gao, J.; Qu, X.; Hasegawa, K.; Sugawara, Y.; Tang, W.; Kokudo, N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci. Trends 2011, 5, 52-56.
11. Bladt, F.; Faden, B.; Friese-Hamim, M.; Knuehl, C.; Wilm, C.; Fittschen, C.; Grädler, U.; Meyring, M.; Dorsch, D.; Jaehrling, F.; et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin. Cancer Res. 2013, 19, 2941-2951.
12. Rubio-Vigueira, B.; Hidalgo, M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin. Pharmacol. Ther. 2009, 85, 217-221.
13. Bertotti, A.; Migliardi, G.; Galimi, F.; Sassi, F.; Torti, D.; Isella, C.; Corà, D.; di Nicolantonio, F.; Buscarino, M.; Petti, C.; et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. CancerDiscov. 2011, 1, 508-523.
14. Gentile, A.; Trusolino, L.; Comoglio, P.M. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008, 27, 85-94.
15. Ogunwobi, O.O.; Puszyk, W.; Dong, H.J.; Liu, C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One 2013, 8, e63765.
16. Qiu, J.; Huang, P.; Liu, Q.; Hong, J.; Li, B.; Lu, C.; Wang, L.; Wang, J.; Yuan, Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J. Transl. Med. 2011, 9, 166.
17. Corso, S.; Giordano, S. Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: From basic research to a clinical perspective. Cancer Discov. 2013, 3, 978-992.
18. Schmidt, C.; Bladt, F.; Goedecke, S.; Brinkmann, V.; Zschiesche, W.; Sharpe, M.; Gherardi, E.; Birchmeier, C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373, 699-702.
19. Bladt, F.; Riethmacher, D.; Isenmann, S.; Aguzzi, A.; Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376, 768-771.
20. Zhang, S.Z.; Pan, F.Y.; Xu, J.F.; Yuan, J.; Guo, S.Y.; Dai, G.; Xue, B.; Shen, W.G.; Wen, C.J.; Zhao, D.H.; et al. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther. 2005, 4, 1577-1584.
21. Xie, B.; Xing, R.; Chen, P.; Gou, Y.; Li, S.; Xiao, J.; Dong, J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J. Surg. Res. 2010, 162, 231-238.
22. Navab, R.; Liu, J.; Seiden-Long, I.; Shih, W.; Li, M.; Bandarchi, B.; Chen, Y.; Lau, D.; Zu, Y.F.; Cescon, D.; et al. Co-expression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 2009, 11, 1292-1300.
23. Koochekpour, S.; Jeffers, M.; Rulong, S.; Taylor, G.; Klineberg, E.; Hudson, E.A.; Resau, J.H.; vande Woude, G.F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997, 57, 5391-5398.
24. Xie, Q.; Bradley, R.; Kang, L.; Koeman, J.; Ascierto, M.L.; Worschech, A.; de Giorgi, V.; Wang, E.; Kefene, L.; Su, Y.; et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc. Natl. Acad. Sci. USA 2012, 2, 570-575.
25. Munshi, N.; Jeay, S.; Li, Y.; Chen, C.R.; France, D.S.; Ashwell, M.A.; Hill, J.; Moussa, M.M.; Leggett, D.S.; Li, C.J. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 2010, 9, 1544-1553.
26. Santoro, A.; Rimassa, L.; Borbath, I.; Daniele, B.; Salvagni, S.; van Laethem, J.L.; van Vlierberghe, H.; Trojan, J.; Kolligs, F.T.; Weiss, A.; et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013, 14, 55-63.
27. Katayama, R.; Aoyama, A.; Yamori, T.; Qi, J.; Oh-hara, T.; Song, Y.; Engelman, J.A.; Fujita, N. Cytotoxic activity of tivantinib (ARQ197) is not due solely to c-Met inhibition. Cancer Res. 2013, 73, 3087-3096.
28. Basilico, C.; Pennacchietti, S.; Vigna, E.; Chiriaco, C.; Arena, S.; Bardelli, A.; Valdembri, D.; Serini, G.; Michieli, P. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin. Cancer Res. 2013, 19, 2381-2392.
29. Spigel, D.R.; Edelman, M.J.; Mok, T.; O'Byrne, K.; Paz-Ares, L.; Yu, W.; Rittweger, K.; Thurm, H.; MetLung Phase III Study Group. Treatment rationale study design for the MetLung trial: A randomized, double-blind Phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer. Clin. Lung Cancer 2012, 13, 500-504.
30. Xie, Q.; Su, Y.; Dykema, K.; Johnson, J.; Koeman, J.; de Giorgi, V.; Huang, A.; Schlegel, R.; Essenburg, C.; Kang, L.; et al. Overexpression of HGF promotes HBV-induced hepatocellular carcinoma progression and is an effective indicator for Met-targeting therapy. Genes Cancer 2013, 4, 247-260.
31. Chisari, F.V.; Klopchin, K.; Moriyama, T.; Pasquinelli, C.; Dunsford, H.A.; Sell, S.; Pinkert, C.A.; Brinster, R.L.; Palmiter, R.D. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59, 1145-1156.
32. Takeda, S.; Liu, H.; Sasagawa, S.; Dong, Y.; Trainor, A.P.; Cheng, E.H.; Hsieh, J.J. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J. Clin. Investig. 2013, 123, 3154-3165.
33. Marquardt, J.U.; Thorgeirsson, S.S. Linking MLL and the HGF-MET signaling pathway in liver cancer. J. Clin. Investig. 2013, 123, 2780-2783.
34. Li, Y.; Tang, Z.Y.; Ye, S.L.; Liu, Y.K.; Chen, J.; Xue, Q.; Chen, J.; Gao, DM.; Bao, W.H. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. 2001, 7, 630-636.
35. Wu, F.S.; Zheng, S.S.; Wu, L.J.; Teng, L.S.; Ma, Z.M.; Zhao, W.H.; Wu, W. Calcitriol inhibits the growth of MHCC97 hepatocellular cell lines by down-modulating c-met and ERK expressions. Liver Int. 2007, 27, 700-707.
36. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205-216.